PureTech Health plc filings document a foreign private issuer with Nasdaq and LSE-listed securities and a biotherapeutics portfolio organized around wholly owned programs and Founded Entities. Its Form 6-K reports furnish annual results, half-year reports, interim financial reviews, unaudited consolidated financial statements and other material-event disclosures that describe portfolio strategy, cash resources, capital-structure matters and clinical or regulatory updates.
The filing record also covers governance and corporate-management matters, including board changes, leadership transitions and shareholder voting topics. Program-related disclosures identify assets such as deupirfenidone for idiopathic pulmonary fibrosis, LYT-200 for myeloid malignancies, and Seaport Therapeutics neuropsychiatric programs, while formal reports provide the regulatory context for PureTech’s operating model, financial reporting and risk-related disclosures.
Citigroup and several of its subsidiaries report a collective beneficial ownership of 13,220,374 ordinary shares of PureTech Health plc, representing 5.5% of the class. The filing names five Citigroup reporting persons and discloses that the position carries shared voting power and shared dispositive power; no sole voting or dispositive authority is reported.
The statement indicates the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing also describes the chain of ownership among the Citigroup entities that hold the position.